CytoMed Therapeutics (GDTC) Total Liabilities (2021 - 2025)

CytoMed Therapeutics has disclosed Total Liabilities across 5 years of filings, most recently posting $872875.4 for Q4 2025.

• In Q4 2025, Total Liabilities rose 13.39% year-over-year to $872875.4; the TTM figure through Dec 2025 stood at $872875.4 (up 13.39% YoY), while the FY2025 annual figure was $865884.8, up 12.48% from the prior year.
• Total Liabilities came in at $872875.4 for Q4 2025 at CytoMed Therapeutics, down from $1.1 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $3.3 million in Q4 2022 to a low of $746073.0 in Q2 2023.
• Average Total Liabilities over 5 years is $1.4 million, with a median of $852971.6 recorded in 2023.
• Year-over-year, Total Liabilities slumped 75.09% in 2023 and jumped 51.55% in 2025.
• Over 5 years, Total Liabilities stood at $2.6 million in 2021, then advanced by 29.99% to $3.3 million in 2022, then tumbled by 75.09% to $833067.9 in 2023, then dropped by 7.6% to $769789.0 in 2024, then increased by 13.39% to $872875.4 in 2025.
• Per Business Quant data, the three most recent Total Liabilities figures were $872875.4 in Q4 2025, $1.1 million in Q2 2025, and $769789.0 in Q4 2024.